Researchers are developing innovative non-viral delivery systems for IL-12 immunotherapy, targeting the tumor microenvironment while minimizing systemic toxicity in ovarian cancer treatment.
IMNN-101, a novel DNA-based COVID-19 vaccine, demonstrated a 2-4 fold increase in neutralizing antibody titers through Week 4 in Phase 1 trial participants.
GRIN Therapeutics' radiprodil receives FDA Breakthrough Therapy designation for treating seizures in patients with GRIN-related neurodevelopmental disorder, showing 86% median reduction in seizure frequency during Phase 1b trials.
PDS Biotech reaffirms the initiation of the VERSATILE-003 Phase 3 clinical trial in Q1 2025 for HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
Imunon's IMNN-001, combined with chemotherapy, demonstrated an 11.1-month improvement in overall survival in patients with advanced ovarian cancer in the OVATION-2 trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.